Schizophrenia is a neuropsychiatric disorder affecting 1% of the world's population. Due to a broad range of symptoms and disease heterogeneity, current therapeutic approaches to treat schizophrenia fail to address all symptomatic manifestations of the disease. Therefore, disease models that reproduce core pathological features of schizophrenia are needed for the elucidation of pathological disease mechanisms. Here, we employ a comprehensive global label-free liquid chromatography-mass spectrometry proteomic (LC-MS 
ABSTRACT
Schizophrenia is a neuropsychiatric disorder affecting 1% of the world's population. Due to a broad range of symptoms and disease heterogeneity, current therapeutic approaches to treat schizophrenia fail to address all symptomatic manifestations of the disease. Therefore, disease models that reproduce core pathological features of schizophrenia are needed for the elucidation of pathological disease mechanisms. Here, we employ a comprehensive global label-free liquid chromatography-mass spectrometry proteomic (LC-MS E ) and metabonomic (LC-MS) profiling analysis combined with targeted proteomics (selected reaction monitoring and multiplex-immunoassay) of serum and brain tissues to investigate a chronic phencyclidine (PCP) rat model, in which glutamatergic hypofunction is induced through noncompetitive NMDAR-receptor antagonism. Using multiplex immunoassay, we identified alterations in the levels of several cytokines (IL-5, IL-2, IL-1β) and fibroblast-growth factor-2. Extensive proteomic and metabonomic brain tissue profiling revealed a more prominent effect of chronic PCP treatment on both the hippocampal proteome and metabonome compared to the frontal cortex. Bioinformatic pathway analysis confirmed prominent abnormalities in NMDA-receptor associated pathways in both brain regions, as well as alterations in other neurotransmitter systems such as kainate, AMPA and GABAergic signalling in the hippocampus and in proteins associated with neurodegeneration. We further identified abundance changes in the level of the superoxide dismutase enzyme (SODC) in both the frontal cortex and hippocampus, which indicate alterations in oxidative stress and substantiates the apoptotic pathway alterations. The present study could lead to an increased understanding of how perturbed glutamate receptor signalling affects other relevant biological pathways in schizophrenia and therefore support drug discovery efforts for improved treatment of patients suffering from this debilitating psychiatric disorder.
Introduction
The potent N-methyl-D-aspartate (NMDA) antagonist phencyclidine (PCP) is one of the most extensively studied animal models of psychiatric disorders. PCP is a psychotomimetic (i.e. able to elicit positive symptoms), 1 which is also able to induce negative 1a, 2 and cognitive 3 symptoms which are core features of schizophrenia and other psychiatric disorders, in both humans and rodents. 4 In addition, it can exacerbate these symptoms in schizophrenia patients. 5 Thus, studies of PCP feature prominently in pharmaceutical drug discovery efforts since most current treatments of schizophrenia are predominately tailored to treat positive symptoms, while negative and cognitive symptoms tend to be more resistant to antipsychotic treatment. Mechanistically, PCP shows an affinity to a variety of receptors [sigma, dopamine D(2) and 5-HT(2) receptors 6 ] but principally acts at the NMDA receptor (NMDAR), where it binds with high affinity to a specific site within the pore of the ion channel, leading to a NMDAR hypofunction. However, PCP is also an antagonist for the dopamine (D2) receptor, inducing abnormalities of dopaminergic transmission in different brain regions in primates 7 and rodents. 8 Thereby, PCP models both glutamate and dopamine dysfunction, which represent the key neurotransmitter systems implicated in the pathophysiology of schizophrenia. 9 However, other neurotransmitter systems, such as serotonin/norepinephrine, 8a, 10 gamma-aminobutyric acid (GABA), 9 , 11 acetylcholine 12 and opioid pathways are also affected by PCP treatment, albeit to a lesser extent. 13 Rodent PCP models are currently among the most commonly used in schizophrenia drug discovery. Previous studies have characterized these models mainly at the behavioural level, with the finding of shared behavioural abnormalities of hyperlocomotion, stereotypy, 14 decreased voluntary sucrose consumption, 15 impaired information processing with cognitive functions of memory 16 and attention and impaired social interaction. 14, 17 The behavioural readouts are thought to correspond to the positive, negative and cognitive symptoms as seen in human schizophrenia. Fewer studies have been performed at the physiological and molecular level, although these have implicated abnormalities of neurotransmitter release and levels, 7a, 8a, 16, 18 dendritic branching, and dendritic spine number, synaptic loss, 19 along with hypofrontality. 20 To date, the molecular mechanisms by which PCP exerts diverse neurochemical, behavioural and clinical effects are still a matter of debate. The first proteomic studies of an acute PCP rat model revealed abnormalities in protein phosphorylation patterns in the frontal cortex 21 and energy metabolism and signal transduction in the hippocampus. 22 Less has been done to investigate chronic PCP (cPCP) effects in the brain, although it has been noted that repeated substance abuse of PCP by humans induces more persistent schizophrenia symptomatology, including psychosis, hallucinations, delusions, formal thought disorder and cognitive dysfunction and social withdrawal. 1a, 23 One extensive proteomic and metabonomic study which investigated the molecular effects in the frontal cortex of a cPCP rat model, led to the identification of subtle abnormalities in proteins involved in calcium signalling and energy metabolism. 24 Here, we attempt to gain further insights into the effects of cPCP treatment using a combination of metabonomic and proteomic profiling of rat brain tissue. Since only subtle molecular changes have been found in the frontal cortex of cPCP treated rats, 24 this study now analyses hippocampal tissue from cPCP treated rats to investigate how this brain region is affected, particularly considering its role in cognition and memory, social behaviour and the (negative) symptom domains. The molecular characterisation will help to improve the understanding of pathophysiological mechanisms associated with psychosis and schizophrenia and support drug discovery and development efforts. and ethical policies of the Home Office. After a 10-day adaptation period, rats were given a daily subcutaneous dose of vehicle (0.9% sterile saline) or PCP hydrochloride (5mg/kg) for 15 consecutive days. All animals were killed by decapitation 30min after the last injection and brain tissues dissected. Behavioural readouts were recorded as described and PCP injection induced the standard increase in locomotor activity and stereotypic movement.
Material and Methods

Animals
24
Serum profiling
Serum preparation, multiplex immunoassays and statistical analysis were performed as described previously. 22, 25 Blood was collected from rats into S-Monovette 7.5 mL serum tubes (Sarstedt; Numbrecht, Germany) and left for 1.5h at room temperature for clotting. The blood was centrifuged at 300 g for 15 min at 4°C. Resulting supernatants (serum samples)
were stored in Low Binding Eppendorf tubes (Hamburg, Germany) at -80°C. Serum samples were analyzed using the RodentMAP, Rat MetabolicMAP and Rat KidneyMAP platforms comprising multiplexed immunoassays of 89 analytes in a Clinical Laboratory Improved Amendments (CLIA)-certified laboratory at Myriad-RBM (Austin, TX, USA). 25 Immunoassays were calibrated using duplicate standard curves for each analyte and raw intensity measurements converted to protein concentrations using proprietary software.
Multiplexed calibrators (eight levels per analyte) and controls (three levels per analyte) were used to monitor key performance parameters, such as lower limit of quantification, precision, of the data were filtered out based on relative standard deviation (RSD). 26 Row-wise normalization to each median reading was employed to adjust for differences among samples and data were log-transformed and pareto-scaled (mean-centered and divided by the square root of standard deviation of each variable) to make features more comparable. Significance
Analysis of Microarray (SAM) was performed using the Siggenes R package. 27 SAM is a well-established statistical method for identification of differentially expressed genes in microarray data analysis and is frequently employed for analysis of high-throughput Omicsdatasets. It is designed to address the false discovery rate (FDR) when running multiple tests and high-dimensional data. SAM assigns a significance score to each variable based on change relative to the standard deviation of repeated measurements. For a variable with scores greater than an adjustable threshold, its relative difference is compared to the distribution estimated by random permutation of the class labels. For each threshold, a certain proportion of the variables in the permutation set will be identified as significantly different by chance. This proportion is used to calculate the FDR.
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Global metabolic profiling
Metabonomic profiling was performed as described previously. 29 In brief, approximately 10mg frontal cortex and 30-50mg hippocampus tissues were weighed out into 2mL bead beater tubes and homogenized with 1.45mL of pre-chilled methanol/water (1:1) and 100µL of 1-mm zirconium beads, using a Precellys bead beater. Homogenisation (6,5000 Hz speed) cycles were 40s, followed by cooling on dry ice, and a further 40s homogenisation and cooling on dry ice. The mixtures were then centrifuged at 10,000g for 10min at 4 o C.
Supernatants (aqueous extracts) were collected and transferred to clean Eppendorf tubes.
Aqueous extracts were dried in a vacuum concentrator (Savant) for at least 180min at 45 o C.
Extracts were resuspended in 120µL of methanol/water (1:1), followed by brief vortexing and sonication, and transferred into 96-well plates for analysis. Quality control (QC) samples were prepared by combining an aliquot (10µL) from each study sample to produce a representative sample -this was used for column conditioning and data quality assessment as described by Want et al.
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UPLC-MS analysis was performed using a Waters XEVO G2 Q-TOF mass spectrometer coupled online to an Acquity UPLC-MS system (Waters Corporation, Milford, MA).
Separation was performed at 0.4mL/min and 50°C, using a 2.1 x 100mm (1.7µm) HSS T3
Acquity column. The injection volume was 5µL and the sample temperature was 4 o C. The mobile phases were 0.1% (vol/vol) formic acid in water (A) and 0.1% (vol/vol) formic acid in methanol (B). The gradient was (99.9% A for 2 min, to 75% A in 4 min; to 20% A in 6 min, to 10% A in 2 min, to 0.1% A in 7 min, 0.1% A for 2 min, to 99.9%A in 4 min). Acquisition was performed in both positive ion mode (1.0kV ESI +) and negative ion mode (1.0kV ESI-).
Source conditions were: source temperature: 120°C, desolvation temperature: 350°C, cone gas flow: 25 L/h, desolvation gas flow: 900 L/h. QC samples were injected ten times at the start of the analytical batch in order to condition the column, then after every ten samples throughout the run to assess instrument stability.
Data were processed using the freeware XCMS 30 using standard parameters. The output consisted of a matrix of metabolite feature m/z, retention time and intensity (peak area)
values. These "metabolite feature" tables were imported into SIMCA-P for multivariate analysis (e.g. PCA) to check data quality and sample outliers. All missing and zero values (0.02% of the data) were replaced by the half of the minimum positive value found within the data. The assumption of this approach is that most of the missing values are caused by low abundance metabolites. Since zero values may cause problems for data normalization (i.e. log), they were replaced with this value. Data were filtered to identify and remove variables that were unlikely to be of use when modelling the data. 10% of data points showing little variance across experimental conditions were filtered based on relative standard deviation.
31
This filtering procedure is highly recommended for chemometric data, which often contains a large amount of noise. Row-wise normalization to sample median was employed to adjust for differences among samples and data was log transformed and pareto-scaled (mean-centered and divided by the square root of standard deviation of each variable) to make features more comparable. P-Values were determined using SAM and corrected to control for multiple hypothesis testing. 28 Ratios were calculated for each molecule as the mean intensity values of cPCP-treated rats divided by those of controls.
Proteomic Sample Preparation
Total lysis sample preparation was performed as previously described using a fractionation buffer containing 7M urea, 2M thiourea, 4 % CHAPS, 2 % ASB14, 70mM dithiotreitol (DTT) and protease inhibitor at a 5:1 (v/w) ratio. 25 concentrations of the lysates were determined using a Bradford assay (Bio-Rad; Hemel Hempstead, UK). Approximately 100 µg sample was precipitated using acetone. After dissolving the precipitate in 50mM ammonium bicarbonate, reduction of sulfhydryl groups were performed with 5mM DTT at 60°C for 30min and alkylation was carried out using 10mM iodacetamide at 37°C for 30 min in the dark and proteins were subsequently digested using trypsin at a 1:50 (w/v) ratio for 17h at 37°C. Reactions were stopped by addition of 8.8 M HCl in a 1:60 (w/w) ratio. Quality control (QC) samples were prepared to monitor machine and preparation performance. For this, an equal amount of each sample was pooled into one sample after the sonication step and then split into multiple aliquots. Each QC sample underwent all experimental steps in parallel with the test samples.
Label-free LC−MS E analysis of frontal cortex and hippocampus tissue
Individual digested brain tissue samples were analyzed in duplicates (0.6 µg protein per duplicate) using a splitless nanoACQUITY -ultra-performance liquid chromatography B was infused via a lock spray for external lock mass correction. The mass spectrometer was operated in V mode, and analyses were carried out using positive nanoESI ion mode.
Collision energy was 5 eV for low-energy scans and ramped from 17 to 40 eV for high- 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 The procedure, quality assessment and data processing were performed as described previously.
22 PLGS2.4 using the Swiss-Prot rodent reference proteome (Uniprot release March 2013) was used for protein identification searches. In order to control the false discovery rate (FDR), data were searched against a decoy database, which was the randomised version of the database mentioned above to conserve amino acid frequencies.
The FDR was set at the default maximum rate of 4%, as applied before. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 dimensions and isotopic regions creation for peak-matching across all runs were calculated using an RT correction of 4 min at the maximum. A single data file was randomly chosen as the master, and all other sample files were aligned to the master in form of a dynamic RT shift. This procedure allowed the improved identification of peptides and proteins in each sample by taking the available data of all samples into account. Features were normalized based on total ion current (TIC). Only features detected in both replicates and in >80 % of samples were included in further analyses. Protein abundance changes were determined using 
Label-based selected reaction monitoring (SRM) mass spectrometry
Digested frontal cortex and hippocampus proteomes were analysed using targeted SRM mass spectrometry on a Xevo TQ-S mass spectrometer (Waters Corporation; Milford, CT, USA) coupled to a nanoAcquity UPLC system (Waters Corporation) as described previously.
32b, 36
The system was comprised of a C18 trapping column (180µmx20mm, 5µm particle size) and a C18 BEH nano-column (75µmx200mm, 1.7mm particle size). The buffers used for separation were (A) 0.1% formic acid and (B) 0.1% formic acid in acetonitrile and the Multiplex SRM assays were developed using a high-throughput strategy. 37 All peptides containing amino acids prone to undergo modifications (e.g., Met, Trp, Asn and Gln), potential ragged ends, or those with lysine/arginine followed by proline or bearing NXT/NXS glycosylation motifs were avoided and only selected when no other options were available. 38 Criteria for selecting tryptic peptides were based on peptide count, uniqueness and quality of transitions. Transitions were selected based on software internal predictions, discovery proteomics data and spectral data [NIST spectral libraries 39 ] and calculated using Skyline version 1.2.0.3425. 40 Quantitative SRM measurements comparing cPCP treated rats and controls were performed in scheduled SRM acquisition mode. Heavy isotope labelled peptide versions (JPT Peptide Technologies GmbH, Berlin, Germany) were spiked in the peptide mixture for accurate quantification and identification. All SRM functions had a 2min
window of the predicted retention time and scan times were 20ms. For each peptide, at least three transitions were monitored for the heavy and light versions. The final transitions, collision energies and retention time windows used for each peptide can be found in the supplementary information (Table S1a, Table S1b ). Samples were run randomized and blocked 41 in triplicates, and blanks and quality control peptide injections (yeast alcohol dehydrogenase; Table S1c ) were run alternating after each biological replicate. Resulting SRM data were analyzed using Skyline and statistical analysis, testing for differential abundance among cPCP treated rats and control animals, was conducted using MSstats. 42 Data pre-processing consisted of a log 2 transformation to stabilise the variance. Quantile normalization was performed based on reference transitions to equalize the median peak intensities of reference transitions from all proteins across all MS runs and adjust the bias to .
Protein set enrichment analysis
Protein set enrichment analysis was carried out as described previously. 44 Therefore, significantly changed proteins were partitioned into three bins, according to their ratio: ratio<1.0; ratio >1.0 and ratio both >1, <1. The R package database org.mouse.eg.db version 2.8.0 was used for gene ontology (GO) term annotation and significant over-representation of an annotated GO term in each bin was determined by the GOstats package (Falcon and Gentleman, 2007). P-values for the GO category 45 "biological pathway" (BP) were calculated by a conditional hypergeometric test, using the entire detected proteome as a background.
One-way hierarchical clustering using "Euclidean distance" as distance function and the "Average Linkage Clustering" method available in the Genesis software, 46 was performed on all significantly enriched GO terms. 
Results
Serum Profiling
We measured serum levels of 89 analytes in rats following cPCP or vehicle treatment using multiplex immunoassays. This was carried out to elucidate how the effects of cPCP treatment are manifested in the peripheral circulation and to identify possible surrogate biomarkers for schizophrenia. In total, 64 analytes were robustly measured with less than 30% missing values. The list of all measured analytes can be found in Table S2 . Following data quality assessment, normalization and scaling, the analysis of the multiplex immunoassays resulted in the identification of five significantly altered analytes in cPCP rat serum (p<0.05) ( Table   1 ). These were predominantly interleukins (IL-5, IL-2, IL-1β) as well as fibroblast growth factor-2 (FGF-2) and the macrophage inflammatory protein 1a (MIP-1α). Table 2 .
Label-free LC-MS
Global metabolic profiling of frontal cortex and hippocampus tissue via UPLC-MS
We employed UPLC-MS for global metabolic profiling analysis of brain tissue. We identified 1057 metabolite features/peaks after filtering based on relative standard deviation across both models and regions. We were not able to detect any significant changed features (Figure 1) . For metabolite peak identification, the top 10 significant hits for the brain regions were selected and database identification performed using the HMDB and the Pubchem database ( Table S4a and S4b). The identifications are preliminary as databank searches alone don't allow for adequate identification. Tandem MS/MS analysis for metabolite identification were not performed.
Label-free LC-MS E proteomic profiling based pathway analysis
Pathway analysis was performed using the total of all changed proteins in the frontal cortex Using Ingenuity Pathway Analysis we identified a decrease in neurodevelopment associated biological functions in the frontal cortex. The hippocampus was associated with a decreased activation of the biological processes "plasticity of synapse", "exocytosis of vesicles", "behaviour" and "spatial memory", and an increased activation of "movement of rodents", "paralysis" and "conditioning" (Figure 3A) . This matches the reported behavioural readouts associated with the cPCP animal model in the literature. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 one pathway ultimately lead to changes in the whole system. The most robust enriched biological functions across both brain regions were associated with small GTPases and Rho signalling proteins.
We further investigated which pathways appear to be affected by examining the interactome of the altered proteins. This overcomes the limitations to be restricted to the range of detectable proteins in the QTOF study, where certain protein classes (e.g. low abundant
proteins, membrane proteins etc.) are frequently not identified and consequently associated pathways will not appear to be enriched. Therefore, we created cytoscape networks based on significantly changed proteins and their interactors using experimentally defined interaction databases for each comparison. GO-term cluster analysis using the reactome pathway information was performed to derive frontal cortex and hippocampus protein networks and an overlap of significant functions was created to identify the most robust pathway signatures across both regions ( Figure 2B ). The protein changes appeared to reflect changes in postsynaptic NMDAR activation events, including "Ras activation upon Ca 2+ -influx through NMDAR" and "CREB phosphorylation through the activation of Ras or CaMKII" as well as two other pathways downstream of the NMDAR. Furthermore the apoptosis-related biological functions of "activation of BAD and BH-3 only proteins" seem to be affected in the frontal cortex. In the case of the hippocampus, a diverse set of other clusters of associated biological functions were found to be enriched in the interactome. This involved AMPA receptor (AMPAR) signalling, kainate receptor signalling, ERK signalling and the TCA cycle.
Selected reaction monitoring validation
We used selective reaction monitoring assays to validate the findings of the proteomic profiling analysis and in order to follow up implications of the bioinformatic pathway changes. Therefore we included key proteins of glutamatergic signalling and proteins already 
Discussion
Currently there is only limited understanding of the molecular pathology underlying schizophrenia. The study of animal models used in drug discovery efforts of schizophrenia can help to decipher the molecular neurobiology of this complex disorder and identify novel targets for improved treatment. However, limited progress has been made in developing novel pharmaco-therapies, partly due to the scarcity of well-characterized animal models. In this study, we investigated the molecular changes associated with cPCP treatment in rats [immunoglobulin secretion and eosinophil activation]. However, an early immune response was also observed through increased levels of IL-1β. When compared to one of our previous studies using the same multiplex immunoassay to investigate serum analyte alterations after acute PCP (5mg/kg) treatment 22 , no overlapping alterations in analyte levels were identified. This study is the first to describe a robust decrease of FGF-2 in PCP-treated rats. FGF-2 has been implicated in the pathophysiology of schizophrenia and the mechanism of action of antipsychotic treatment response. 55 Furthermore, it has also been implicated in depression 56 and as a marker of antidepressant effects. 57 Based on the psychotomimetic and antidepressant effect of NMDAR-antagonists, especially ketamine, perturbations of FGF-2 regulation might be relevant for both disorders. Future work needs to clarify if these peripheral changes contribute to the specific effect of PCP. With respect to the brain pathology, it is likely that FGF-2 levels in serum resemble levels in the brain since this growth factor can cross the blood-brain barrier. 58 FGF-2 has been implicated in neurogenesis and gliogenesis during development as well as in adulthood 59 via its role as a neurotrophic factor. This is consistent 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 and differentiating neural progenitors in the hippocampus and this may have an effect on behaviours relevant to psychiatric disorders. 60 In general, the brain tissue profiling identified changes in a wide range of proteins induced by cPCP treatment. Individually, protein changes were subtle indicating homeostatic disequilibrium. Therefore we employed several pathway analyses incorporating all changes to reveal which signalling networks and cellular mechanism are dysregulated. In table 2 we also pinpoint proteins with larger fold-changes, which might represent the key drivers for the identified pathway alterations. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 expression and neurochemistry) and animal model 64 studies. Our previous study investigating the effects of acute PCP treatment has indicated that the hippocampus is more affected than the frontal cortex. 22 Many of the findings of the proteomic shotgun analysis of acute PCP treatment are consistent with findings in this study (Table 3) . 22 Fifteen of the 17 significantly changed proteins in the hippocampus of the acute PCP model overlapped with the findings of this study. The stronger effects induced by chronic treatment might be secondary to neurodegenerative pathologies. Neurodegeneration has been associated with PCP treatment in humans and animal models 65 . Consistent with the proteomic analysis of frontal cortex of a similar cPCP rat model, 24 we also only detected subtle changes in the frontal cortex. In comparison to this study, we detected overlapping pathways in oxidative stress (DJ-1 and SODC1 proteins) and mitochondrial related proteins (GOT2 and PKLR), and calcium signalling. For instance, neurogranin, one of the strongest alterations which we found in the frontal cortex, regulates calmodulin affinity for Ca
2+
.
In this investigation, we also identified proteomic correlates for behavioural functions based on hippocampus proteomic abnormalities, such as decreased activation of "behaviour"
and "spatial memory" derived from the cPCP-induced hippocampus proteome alterations as well as increased activation of the biological functions "movement", "paralysis" and "conditioning". In the case of the frontal cortex the study was unable to identify any associations of the proteomic alterations with behavioural readouts. The hippocampal alterations were further associated with decreased plasticity of synapse and neurotransmitter release at the proteome level and lipid metabolism at the metabonome level. The hippocampal pathology in schizophrenia appears to be linked with at least some of the cognitive deficits, given the central mnemonic roles of this brain region. 66 These key changes most likely reflect alterations in the precise organisation and functioning of neural circuits which connect it with other structures, notably the prefrontal cortex. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Post-mortem studies have provided increasing evidence for glutamatergic neurotransmission abnormalities in schizophrenia. Such studies have found hippocampal changes including reduced expression of one or more subunits for all three ionotropic glutamate receptors (NMDAR, AMPAR, and kainite receptor). In addition, recently described susceptibility genes for schizophrenia all act upon glutamatergic synaptic transmission, which may be part of the core pathophysiology. 67 We This study also detected changes in Ca
, opioid, kainate and ERK signalling, which have previously been associated with NMDAR hypofunction. 32b, 68 For instance, repeated administration of PCP reduces sigma-1 receptors in the hippocampus. 13 Interestingly, effects on neurotransmitter metabolism were identified in the hippocampus, as shown by IPA and cytoscape pathway analysis. The most robust protein findings were associated with GABAreceptor pathways. A compromised GABAergic system has been hypothesized to be involved in schizophrenia. Notably, NMDAR hypofunction has been proposed to promote deficits in GABAergic signalling 69 and PCP administration during neurodevelopment affects the functionality of GABA interneurons in later life. 70 One action of NMDA antagonists is to reduce the excitation of fast-spiking GABA interneurons, resulting in disinhibition of pyramidal cells. Overactive pyramidal cells, notably those in the hippocampus, can induce a hyperdopaminergic state that produces psychosis. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Finally, we identified alterations in the protein level of the superoxide dismutase enzyme (SODC) in both the frontal cortex and hippocampus, which is part of the reactive oxygen species (ROS) defence system. Oxidative stress damages many cell structures such as protein, lipids and DNA 71 . Impairments in energy metabolism are common traits of psychiatric disorders and were previously identified by functional assays, gene and protein expression studies as well as linkage analysis in schizophrenia patients. 72 PCP administration to rats results in reduced rates of oxygen uptake into mitochondria isolated from brain tissue 73 and a meta-analysis of 44 studies identified a total antioxidant status in serum and plasma as a state marker for first-episode psychosis. 74 For these reasons, molecules that possess antioxidant and anti-inflammatory properties may be useful as potential novel treatments in the first stages of schizophrenia. 75 This comprehensive proteomic and metabonomic study of the cPCP rat model provides novel molecular evidence showing that different neurotransmitter systems are affected through PCP treatment and that these effects occur primarily in the hippocampus.
Importantly we were able to find potential molecular correlates which may be linked to the behavioural readouts in this model. Further studies are warranted to investigate this possibility as this could lead to identification of novel therapeutic targets involved in regulation of psychiatric symptoms. Furthermore, understanding the changes in glutamate neurotransmission in schizophrenia may facilitate the discovery of novel targets for pharmacological interventions, which are especially needed for the cognitive and negative symptoms in schizophrenia. 21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 TABLES. Table 1 : Analysis of protein levels in serum of PCP-treated (n=8) and saline-treated rats (n=8) using multiplexed immunoassays. P-Values were determined using SAM.
27 FC = Fold change. CT = vehicle-treated rats 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Computational Pathway analysis of the cPCP-induced proteomic alterations in frontal cortex and hippocampus brain tissue. A) Ingenuity Pathway Analysis (IPA) showing significantly decreased (black bars, minus sign) and increased (white bars, plus sign) biological functions in cPCP rat brain regions. Functions (p<0.05) are shown with an activation score (z-score) >1 (increased activation) or <-1 (decreased activation). B) Cytoscape generated interaction clusters based on the altered proteins (p<0.05) in the frontal cortex and hippocampus. Protein interaction networks were created using the IMEx databases and ClueGO was applied to identify clusters within. Overlapping GO-terms amongst the clusters are indicated by grey shading. Circles represent different GO-terms within the cluster. C) Functional enrichment analysis of significantly changed proteins in frontal cortex and hippocampus of the cPCP rat. Proteins were split into fold-change bins for separate analyses. Colour coded z-score transformed p-values indicate the significance of the enrichment for each bin as indicated. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 for TOC only 254x190mm (96 x 96 DPI) Page 38 of 38 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
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